1
|
Mussayev A, Alimbayev S, Tanaliev N, Kuanyshbek A, Marat A, Lesbekov T, Raissov Y, Sadykova A, Kamila AK, Mukarov M, Pya Y. Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up. Front Cardiovasc Med 2023; 10:1152280. [PMID: 37485262 PMCID: PMC10361752 DOI: 10.3389/fcvm.2023.1152280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 06/06/2023] [Indexed: 07/25/2023] Open
Abstract
Generally, the dysfunction or failure of bioprosthetic heart valves (BHVs) is managed by replacement surgery. In the case of tricuspid valve dysfunction, re-do surgery is rarely attempted because of the critically high risk of developing pulmonary hypertension, pulmonary embolism, and intraoperative mortality. Hence, transcatheter tricuspid repair and replacement procedures are preferred. More recently, transcatheter valve-in-valve (ViV) treatments have gained importance because of their less invasiveness, especially for patients with prior surgeries. Encouraging evidence of the safety and effectiveness of a novel balloon-expandable (BE) transcatheter heart valve (THV)-the Myval THV-has been reported for ViV procedures. Here, we present a case-series of 5 patients, in whom tricuspid ViV procedure was performed using BE Myval THV, implanted supra-annularly by anchoring onto the deteriorated BHV. This case-series details the procedural steps to prevent in-hospital adverse events and early (30-day) mortality and the challenges during tricuspid ViV interventions.
Collapse
Affiliation(s)
- Abdurashid Mussayev
- Head of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Serik Alimbayev
- Head of Structural Heart Diseases, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Nursultan Tanaliev
- Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aidyn Kuanyshbek
- Head of the Department of Anesthesiology, Resuscitation and Intensive Care, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aripov Marat
- Head of Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Timur Lesbekov
- Head of the Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Yerkezhan Raissov
- Resident of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Aigerim Sadykova
- Chief Nurse of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Askarovna Kenzhebayeva Kamila
- Clinical Cardiologist, Central Hospital with a Polyclinic of the Ministry of Internal Affairs, Astana, Republic of Kazakhstan
| | - Murat Mukarov
- Head of the Department of Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan
| | - Yuriy Pya
- Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan
| |
Collapse
|
2
|
Di Mauro M, Bonalumi G, Giambuzzi I, Dato GMA, Centofanti P, Corte AD, Ratta ED, Cugola D, Merlo M, Santini F, Salsano A, Rinaldi M, Mancuso S, Cappabianca G, Beghi C, De Vincentiis C, Biondi A, Livi U, Sponga S, Pacini D, Murana G, Scrofani R, Antona C, Cagnoni G, Nicolini F, Benassi F, De Bonis M, Pozzoli A, Pano M, Nicolardi S, Falcetta G, Colli A, Musumeci F, Gherli R, Vizzardi E, Salvador L, Picichè M, Paparella D, Margari V, Troise G, Villa E, Dossena Y, Lucarelli C, Onorati F, Faggian G, Mariscalco G, Maselli D, Barili F, Parolari A, Lorusso R. Similar outcome of tricuspid valve repair and replacement for isolated tricuspid infective endocarditis. J Cardiovasc Med (Hagerstown) 2022; 23:406-413. [PMID: 35645032 DOI: 10.2459/jcm.0000000000001310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
AIMS To compare early and late mortality of acute isolated tricuspid valve infective endocarditis (TVIE) treated with valve repair or replacement. METHODS Patients who were surgically treated for TVIE from 1983 to 2018 were retrieved from the Italian Registry for Surgical Treatment of Valve and Prosthesis Infective Endocarditis. All the patients were followed up by means of phone interview or calling patient referral physicians or cardiologists. Kaplan-Meier method was used to assess late survival and survival free from TVIE recurrence with log-rank test for univariate comparison. The primary end points were early mortality (30 days after surgery) and long-term survival free from TVIE recurrence. RESULTS A total of 4084 patients were included in the registry. Among them, 149 patients were included in the study. Overall, 77 (51.7%) underwent TV repair and 72 (48.3%) TV replacement. Early mortality was 9% (13 patients). Expected early mortality according to EndoSCORE was 12%. The TV repair showed lower mortality and major complication rate (7% and 16%), compared with TV replacement (11% and 25%), but statistical significance was not reached. Median follow-up was 19.1 years (14.3-23.8). Late deaths were 30 and IE recurrences were 5. No difference in cardiac survival free from IE was found between the two groups after 20 years (80 ± 6% Repair Group vs 59 ± 13% Replacement Group, P = 0.3). CONCLUSIONS Overall results indicate that once surgically addressed, TVIE has a low recurrence rate and excellent survival, apparently regardless of the type of surgery used to treat it.
Collapse
Affiliation(s)
- Michele Di Mauro
- Cardio-Thoracic Surgery Department, Heart & Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | | | | | | | | | | | | - Diego Cugola
- Cardiac Surgery, AO Papa Giovanni XXIII, Bergamo
| | | | | | - Antonio Salsano
- Cardiac Surgery, IRCCS San Martino-IST, University Hospital, Genova
| | - Mauro Rinaldi
- Cardiac Surgery, Molinette Hospital, University of Turin, Turin
| | - Samuel Mancuso
- Cardiac Surgery, Molinette Hospital, University of Turin, Turin
| | | | | | | | - Andrea Biondi
- Cardiac Surgery, San Donato IRCCS Hospital, San Donato Milanese, Milan
| | - Ugolino Livi
- Cardiac Surgery, S. Maria Misericordia Hospital, University of Udine, Udine
| | - Sandro Sponga
- Cardiac Surgery, S. Maria Misericordia Hospital, University of Udine, Udine
| | - Davide Pacini
- Cardiac Surgery, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna
| | - Giacomo Murana
- Cardiac Surgery, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna
| | | | - Carlo Antona
- Cardiac Surgery, Sacco Hospital, University of Milan, Milan
| | | | - Francesco Nicolini
- Cardiac Surgery, Maggiore University Hospital, University of Parma, Parma
| | - Filippo Benassi
- Cardiac Surgery, Maggiore University Hospital, University of Parma, Parma
| | | | | | - Marco Pano
- Cardiac Surgery, Vito Fazi Hospital, Lecce
| | | | - Giosuè Falcetta
- Cardiac Surgery, AO Pisana University Hospital, University of Pisa, Pisa
| | - Andrea Colli
- Cardiac Surgery, AO Pisana University Hospital, University of Pisa, Pisa
| | | | | | | | | | | | | | | | | | | | | | - Carla Lucarelli
- Cardiac Surgery, University Hospital, University of Verona, Verona, Italy
| | - Francesco Onorati
- Cardiac Surgery, University Hospital, University of Verona, Verona, Italy
| | - Giuseppe Faggian
- Cardiac Surgery, University Hospital, University of Verona, Verona, Italy
| | | | | | | | - Alessandro Parolari
- Department of Universitary Cardiac Surgery, IRCCS Policlinico San Donato, San Donato Milanese.,Department of Biomedical Sciences for Health, Università di Milano, Milan, Italy
| | - Roberto Lorusso
- Cardio-Thoracic Surgery Department, Heart & Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | |
Collapse
|
6
|
Viotto G, Paim L, Souza R, Aprígio J, Lacerda L, Pomerantzeff P, Jatene MB, Palma JH, Jatene FB. Early outcomes of transcatheter tricuspid valve-in-valve implantation: a case series. Interact Cardiovasc Thorac Surg 2019; 29:59-63. [PMID: 30689872 DOI: 10.1093/icvts/ivy362] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 11/10/2018] [Accepted: 11/19/2018] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES In this study, we sought to evaluate early outcomes of transcatheter valve-in-valve implantation in patients with a degenerated bioprosthesis in the tricuspid position. METHODS We used a prospective study, which included patients with a degenerated bioprosthesis in the tricuspid position who were considered high-risk by our heart team and who underwent a valve-in-valve implantation. The procedures were performed via transjugular venous access and were done with the patient under general anaesthesia with transoesophageal echocardiographic and fluoroscopic guidance. Perioperative data were analysed, and the patients were followed prospectively. RESULTS Seven patients were included. The baseline diagnoses were 3 patients with Ebstein's anomaly, 1 patient with tetralogy of Fallot, 1 patient with neonatal endocarditis, 1 patient with ventricular septal defect with a double tricuspid lesion and 1 patient with rheumatic mitral and tricuspid valve who underwent a combined transapical mitral and transjugular tricuspid valve-in-valve implantation. The mean age was 33 ± 10.8 years and 57.1% of the patients were men. The mean number of previous thoracotomies was 3 ± 2 (range 1-5) procedures. The mean follow-up was 1.24 years. The implant was successful in all cases, and there was no need for conversion to open surgery. There were no deaths during the study period, and all patients are currently in the New York Heart Association functional class I/II. There was a statistically significant difference when the mean transvalvular gradients preimplantation and postimplantation were compared (P < 0.001). CONCLUSIONS Percutaneous tricuspid valve implantation should be considered a safe and effective therapy and stands as a viable, reliable alternative for the treatment of a degenerated bioprosthesis in high-surgical-risk/inoperable patients.
Collapse
Affiliation(s)
- Guilherme Viotto
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Leonardo Paim
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Renato Souza
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Joaquim Aprígio
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Lucas Lacerda
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Pablo Pomerantzeff
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Marcelo B Jatene
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - José Honório Palma
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| | - Fabio B Jatene
- Cardiopneumology Department, InCor-Heart Institute of the University of São Paulo Clinic's Hospital, São Paulo, Brazil
| |
Collapse
|